Progyny (PGNY) to Release Earnings on Thursday

Progyny (NASDAQ:PGNY) is projected to post its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Progyny to post earnings of $0.37 per share and revenue of $299.2270 million for the quarter. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS.Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:45 PM ET.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). The business had revenue of $332.87 million during the quarter, compared to the consensus estimate of $315.70 million. Progyny had a return on equity of 10.69% and a net margin of 4.28%.The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.17 earnings per share. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Price Performance

Progyny stock traded up $0.32 during mid-day trading on Tuesday, hitting $18.75. The company’s stock had a trading volume of 256,768 shares, compared to its average volume of 1,386,595. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of 31.60, a price-to-earnings-growth ratio of 1.59 and a beta of 1.29. The business has a 50 day moving average price of $21.21 and a 200-day moving average price of $21.91. Progyny has a 12 month low of $13.39 and a 12 month high of $26.76.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PGNY. JPMorgan Chase & Co. raised their target price on Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Raymond James Financial set a $28.00 target price on Progyny in a research note on Friday, August 8th. Leerink Partnrs raised Progyny from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 8th. Finally, Truist Financial raised their target price on Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.44.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 2,398 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the transaction, the executive vice president owned 79,697 shares of the company’s stock, valued at approximately $1,829,843.12. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kevin K. Gordon sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the transaction, the director directly owned 12,501 shares of the company’s stock, valued at $275,522.04. This represents a 16.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,895 shares of company stock valued at $179,311 in the last ninety days. Insiders own 9.40% of the company’s stock.

Institutional Investors Weigh In On Progyny

A number of institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. grew its holdings in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after buying an additional 545,431 shares during the last quarter. Bank of America Corp DE lifted its position in Progyny by 4.3% during the second quarter. Bank of America Corp DE now owns 684,133 shares of the company’s stock valued at $15,051,000 after purchasing an additional 28,151 shares during the period. Invesco Ltd. lifted its position in Progyny by 37.4% during the second quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after purchasing an additional 103,253 shares during the period. Public Sector Pension Investment Board lifted its position in Progyny by 8.2% during the second quarter. Public Sector Pension Investment Board now owns 254,208 shares of the company’s stock valued at $5,593,000 after purchasing an additional 19,240 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Progyny by 6.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after purchasing an additional 14,297 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.